Last updated: February 21, 2024
Sponsor: Jasper Gerritsen
Overall Status: Active - Recruiting
Phase
N/A
Condition
Glioblastoma Multiforme
Gliomas
Astrocytoma
Treatment
Best supportive care
Re-resection
Temozolomide
Clinical Study ID
NCT06283927
MEC-2020-0812-5
Ages 18-90 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age ≥18 years and ≤90 years
- Tumor recurrence according to the RANO criteria of a previously diagnosed glioblastomabased on the WHO 2021 classification for glioma
- The tumor is suitable for resection (according to neurosurgeon)
- Written informed consent
Exclusion
Exclusion Criteria:
- Tumors of the cerebellum, brainstem, or midline
- Medical reasons precluding MRI (e.g., pacemaker)
- Inability to give written informed consent
- Secondary high-grade glioma due to malignant transformation from low-grade glioma
- Clinical data unavailable for the newly diagnosed setting
Study Design
Total Participants: 464
Treatment Group(s): 6
Primary Treatment: Best supportive care
Phase:
Study Start date:
January 01, 2023
Estimated Completion Date:
January 01, 2028
Study Description
Connect with a study center
University Hospital Leuven
Leuven,
BelgiumActive - Recruiting
University Hospital Heidelberg
Heidelberg,
GermanyActive - Recruiting
Technical University Munich
Munich,
GermanySite Not Available
Erasmus MC
Rotterdam, Zuid-Holland 3015 CE
NetherlandsActive - Recruiting
Medical Center Haaglanden
The Hague, Zuid-Holland 2261 CP
NetherlandsActive - Recruiting
Inselspital Universitätsspital Bern
Bern,
SwitzerlandSite Not Available
University of California, San Francisco
San Francisco, California 94143
United StatesActive - Recruiting
Massachusetts General Hospital
Boston, Massachusetts 02114
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.